T
Timothy J. Price
Researcher at University of Adelaide
Publications - 471
Citations - 25351
Timothy J. Price is an academic researcher from University of Adelaide. The author has contributed to research in topics: Colorectal cancer & Cetuximab. The author has an hindex of 50, co-authored 442 publications receiving 20155 citations. Previous affiliations of Timothy J. Price include Martin Luther University of Halle-Wittenberg & Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Christos S. Karapetis,Shirin Khambata-Ford,Derek J. Jonker,Christopher J. O'Callaghan,Dongsheng Tu,Niall C. Tebbutt,R. John Simes,Haji Chalchal,Jeremy Shapiro,Sonia Robitaille,Timothy J. Price,Lois E. Shepherd,Heather-Jane Au,Christiane Langer,Malcolm J. Moore,John Zalcberg +15 more
TL;DR: Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ra did benefit fromcetuxIMab.
Journal ArticleDOI
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem,Andrés Cervantes,René Adam,Alberto Sobrero,J.H.J.M. van Krieken,Dan Aderka,E. Aranda Aguilar,Alberto Bardelli,Al B. Benson,György Bodoky,Fortunato Ciardiello,André D'Hoore,Eduardo Díaz-Rubio,J.-Y. Douillard,Michel Ducreux,Alfredo Falcone,Axel Grothey,Thomas Gruenberger,Karin Haustermans,Volker Heinemann,Paulo M. Hoff,C.-H. Köhne,R. Labianca,Pierre Laurent-Puig,Brigette B.Y. Ma,Tim Maughan,Kei Muro,Nicola Normanno,Pia Österlund,Pia Österlund,Wim J.G. Oyen,Demetris Papamichael,George Pentheroudakis,Per Pfeiffer,Timothy J. Price,C.J.A. Punt,Jens Ricke,Arnaud Roth,R. Salazar,Werner Scheithauer,H.-J. Schmoll,Josep Tabernero,Julien Taieb,Sabine Tejpar,Harpreet Wasan,Takayuki Yoshino,Aziz Zaanan,Dirk Arnold +47 more
TL;DR: These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
Journal ArticleDOI
Cetuximab for the Treatment of Colorectal Cancer
Derek J. Jonker,Christopher J. O'Callaghan,Christos S. Karapetis,John Zalcberg,Dongsheng Tu,Heather-Jane Au,Scott R. Berry,Marianne Krahn,Timothy J. Price,R. John Simes,Niall C. Tebbutt,Guy van Hazel,Rafal Wierzbicki,Christiane Langer,Malcolm J. Moore +14 more
TL;DR: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed.
Journal ArticleDOI
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H.-J. Schmoll,E. Van Cutsem,Alexander Stein,Vincenzo Valentini,Bengt Glimelius,Bengt Glimelius,Karin Haustermans,Bernard Nordlinger,C.J.H. van de Velde,Judith Balmaña,Jaroslaw Regula,Iris D. Nagtegaal,Regina G. H. Beets-Tan,D Arnold,Fortunato Ciardiello,Paulo M. Hoff,David J. Kerr,C.-H. Köhne,Roberto Labianca,Timothy J. Price,Werner Scheithauer,Alberto Sobrero,Josep Tabernero,Dan Aderka,S Barroso,György Bodoky,J.-Y. Douillard,H El Ghazaly,Jorge Gallardo,August Garin,Rob Glynne-Jones,Karin Jordan,A Meshcheryakov,D Papamichail,Per Pfeiffer,Ioannis Souglakos,Serdar Turhal,Andrés Cervantes +37 more
TL;DR: This ESMO guideline is recommended to be used as the basis for treatment and management decisions, delivering a clear proposal for diagnostic and treatment measures in each stage of rectal and colon cancer and the individual clinical situations.
Journal ArticleDOI
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon,Karen Rex,Anne Y. Saiki,Christopher Mohr,Keegan Cooke,Dhanashri Bagal,Kevin Gaida,Tyler Holt,Charles G. Knutson,Neelima Koppada,Brian A. Lanman,Jonathan Werner,Aaron S. Rapaport,Tisha San Miguel,Roberto Ortiz,Roberto Ortiz,Tao Osgood,Ji Rong Sun,Xiaochun Zhu,Xiaochun Zhu,John D. McCarter,Laurie P. Volak,Laurie P. Volak,Brett E. Houk,Marwan Fakih,Bert H. O'Neil,Timothy J. Price,Gerald Steven Falchook,Jayesh Desai,James Kuo,Ramaswamy Govindan,David S. Hong,Wenjun Ouyang,H. Henary,Tara Arvedson,Victor J. Cee,J. Russell Lipford +36 more
TL;DR: Treatment of KRASG 12C-mutant cancer cells with the KRAS(G12C) inhibitor AMG 510 leads to durable response in mice, and anti-tumour activity in patients suggests that AMG510 could be effective in patients for whom treatments are currently lacking.